Search Results - "Prummel, M."

On Assessing Responsiveness of Health-Related Quality of Life Instruments: Guidelines for Instrument Evaluation by Terwee, C B, Dekker, F W, Wiersinga, W M, Prummel, M F, Bossuyt, P M M

“…A lack of clarity exists about the definition and adequate approach for evaluating responsiveness. An overview is presented of different categories of…”
Get full text

Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial by Wakelkamp, I. M. M. J., Baldeschi, L., Saeed, P., Mourits, M. P., Prummel, M. F., Wiersinga, W. M.

“…Summary Objective  Only a small percentage of Graves’ ophthalmopathy (GO) patients develop optic neuropathy with impending loss of visual acuity. Therapy with…”
Get full text

TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients by Wakelkamp, I. M. M. J., Bakker, O., Baldeschi, L., Wiersinga, W. M., Prummel, M. F.

“…Summary objective From in vitro studies using cultures of orbital fibroblasts, it has become clear that cytokines play an important role in the orbital…”
Get full text

Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers by Wiersinga, W M, Perros, P, Kahaly, G J, Mourits, M P, Baldeschi, L, Boboridis, K, Boschi, A, Dickinson, A J, Kendall-Taylor, P, Krassas, G E, Lane, C M, Lazarus, J H, Marcocci, C, Marino, M, Nardi, M, Neoh, C, Orgiazzi, J, Pinchera, A, Pitz, S, Prummel, M F, Sartini, M S, Stahl, M, von Arx, G

Get full text

Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments by Terwee, C. B., Dekker, F. W., Mourits, M.P., Gerding, M. N., Baldeschi, L., Kalmann, R., Prummel, M. F., Wiersinga, W. M.

“…The Graves' ophthalmopathy quality of life questionnaire (GO‐QOL) is the first instrument available to measure health‐related quality of life (HRQL) of…”
Get full text

Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy by Gerding, Martin N., van der Meer, Jolanda W. C., Broenink, Margreet, Bakker, Onno, Wiersinga, Wilmar M., Prummel, Mark F.

“…OBJECTIVE Graves' ophthalmopathy (GO) and Graves' hyperthyroidism are closely associated diseases and thought to be caused by the same autoimmune process. An…”
Get full text

Soluble IL‐2 receptor levels in patients with Graves’ophthalmopathy by PRUMMEL, M. F, WIERSINGA, W. M., GAAG, R., MOURITS, M. P, KOORNNEEF, L.

“…SUMMARY In various autoimmune diseases circulating levels of soluble 1L‐2 receptor (sIL‐2R) seem to be related to disease activity. Because reliable parameters…”
Get full text

Development of a disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy: the GO-QOL by Terwee, Caroline B, Gerding, Martin N, Dekker, Friedo W, Prummel, Mark F, Wiersinga, Wilmar M

“…AIM To develop a reliable and valid disease specific quality of life questionnaire (the GO-QOL) for patients with Graves’ ophthalmopathy (GO), that can be used…”
Get full text

Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy by Terwee, C. B., Prummel, M. F., Gerding, M. N., Kahaly, G. J., Dekker, F. W., Wiersinga, W. M.

“…Summary Objective  The concept of disease activity in Graves’ ophthalmopathy (GO) might explain why as many as one‐third of patients do not respond to…”
Get full text

A questionnaire survey on the management of Graves’ orbitopathy in Europe by Perros, P, Baldeschi, L, Boboridis, K, Dickinson, A J, Hullo, A, Kahaly, G J, Kendall-Taylor, P, Krassas, G E, Lane, C M, Lazarus, J H, Marcocci, C, Marino, M, Mourits, M P, Nardi, M, Orgiazzi, J, Pinchera, A, Pitz, S, Prummel, M F, Wiersinga, W M

“…Objective: To determine management patterns among clinicians who treat patients with Graves’ orbitopathy (GO) in Europe. Design and methods: Questionnaire…”
Get full text

Both Th1‐ and Th2‐derived cytokines in serum are elevated in Graves' ophthalmopathy by Wakelkamp, I. M. M. J., Gerding, M. N., Van Der Meer, J.W. C., Prummel, M. F., Wiersinga, W. M.

“…Increased serum cytokine levels have been reported in patients with autoimmune thyroid disease, but less is known about their levels in patients with Graves'…”
Get full text

Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy by Prummel, M F, Mourits, M P, Blank, L, Berghout, A, Koornneef, L, Wiersinga, W M

“…Corticosteroids are usually given for management of Graves' ophthalmopathy, but they have many and serious side-effects. By comparison, retrobulbar irradiation…”
Get more information

Establishment of reference values for endocrine tests. Part IV: Adrenal insufficiency by ENDERT, E, OUWEHAND, A, FLIERS, E, PRUMMEL, M. F, WIERSINGA, W. M

“…The short Synacthen test, the overnight metyrapone test and the insulin tolerance test are frequently used in the evaluation of patients suspected of adrenal…”
Get full text

Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO) survey by McKeag, David, Lane, Carol, Lazarus, John H, Baldeschi, Lelio, Boboridis, Kostas, Dickinson, A Jane, Hullo, A Iain, Kahaly, George, Krassas, Gerry, Marcocci, Claudio, Marinò, Michele, Mourits, Maarten P, Nardi, Marco, Neoh, Christopher, Orgiazzi, Jacques, Perros, Petros, Pinchera, Aldo, Pitz, Susanne, Prummel, Mark F, Sartini, Maria S, Wiersinga, Wilmar M

“…Background: This study was performed to determine clinical features of dysthyroid optic neuropathy (DON) across Europe. Methods: Forty seven patients with DON…”
Get full text

Effects of Graves' ophthalmopathy on quality of life by Wiersinga, W M, Prummel, M F, Terwee, C B

“…General health-related quality of life is markedly impaired in patients with Graves' ophthalmopathy (GO), and even worse than in patients with other chronic…”
Get full text

Functional thyrotropin receptor expression in the pituitary folliculo-stellate cell line TtT/GF by Brokken, L J S, Bakker, O, Wiersinga, W M, Prummel, M F

“…Thyrotropin secretion from the anterior pituitary is regulated mainly through TRH and thyroid hormones. Recent findings of a TSH receptor (TSHR) on…”
Get more information

Smoking and Risk of Graves' Disease by Prummel, Mark F, Wiersinga, Wilmar M

“…Objective.—To assess if smoking is associated with Graves' disease and, if so, to ascertain whether this association persists when controlling for confounding…”
Get full text

Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument by Gerding, M N, Terwee, C B, Dekker, F W, Koornneef, L, Prummel, M F, Wiersinga, W M

“…To assess the impact of Graves' ophthalmopathy (GO) on quality of life using a general questionnaire, we performed a descriptive study on consecutive…”
Get more information

Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach by Mourits, M P, Koornneef, L, Wiersinga, W M, Prummel, M F, Berghout, A, van der Gaag, R

“…Patients with serious inflammatory Graves' ophthalmopathy should be treated with anti-inflammatory drugs or radiotherapy to prevent complications like…”
Get full text

Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy by Mourits, Maarten Ph, Prummel, Mark F., Wiersinga, Wilmar M., Koornneef, L.

“…OBJECTIVE Approximately 35% of patients with Graves' ophthalmopathy do not respond to immunosuppressive treatment. A possible explanation for this finding is…”
Get full text